Digest Network Come funziona
Network
/
Società
Ne
Non verificato

Neurogene Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

33 comunicati stampa

Guarda tutti i comunicati
05/02/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Scienza
Farmaceutica
Neurogene to Participate in Upcoming Investor Conferences
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
04/02/2026
Biotecnologia
Farmaceutica
Salute
Finanza
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Eventi
Industria
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Web e Social Network
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
04/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Web e Social Network
Eventi
Industria
Scienza
Infanzia
Biotecnologia
Medicina - Varie
Salute
Vetrine/Shopping
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Scienza
Sanità
Salute
Biotecnologia
Web e Social Network
Eventi
Industria
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Biotecnologia
Salute
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Eventi
Industria
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Fonte
Neurogene Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0